Ipca Laboratories (IPCALAB) 주식 개요
제약 회사인 Ipca Laboratories Limited는 인도, 유럽, 아프리카, 미주, 아시아, CIS 및 오스트레일리아의 다양한 치료 부문을 위한 제형 및 활성 제약 성분(API)을 제조 및 판매하는 회사입니다. 자세히 보기
IPCALAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ipca Laboratories Limited 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | ₹1,778.90 |
| 52주 최고가 | ₹1,788.30 |
| 52주 최저가 | ₹1,251.60 |
| 베타 | 0.049 |
| 1개월 변동 | 14.42% |
| 3개월 변동 | 19.53% |
| 1년 변동 | 25.03% |
| 3년 변동 | 134.28% |
| 5년 변동 | 70.27% |
| IPO 이후 변동 | 4,581.32% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.
내러티브 업데이트 • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.
내러티브 업데이트 • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.분석 기사 • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Recent updates
내러티브 업데이트 • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.내러티브 업데이트 • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.내러티브 업데이트 • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.분석 기사 • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...내러티브 업데이트 • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).내러티브 업데이트 • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).내러티브 업데이트 • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.내러티브 업데이트 • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.분석 기사 • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...분석 기사 • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...내러티브 업데이트 • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.내러티브 업데이트 • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).분석 기사 • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...내러티브 업데이트 • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.내러티브 업데이트 • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).내러티브 업데이트 • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.분석 기사 • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...내러티브 업데이트 • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.내러티브 업데이트 • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.분석 기사 • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...분석 기사 • Sep 05
If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...분석 기사 • Jul 08
Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...분석 기사 • Jun 24
Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...분석 기사 • Jun 01
Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Ipca Laboratories Limited ( NSE:IPCALAB ) released its yearly result to the market...분석 기사 • May 22
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 51.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...분석 기사 • Feb 16
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders might have noticed that Ipca Laboratories Limited ( NSE:IPCALAB ) filed its third-quarter result this time...분석 기사 • Jan 10
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Dec 20
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
With a price-to-earnings (or "P/E") ratio of 61.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...
새로운 내러티브 • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.분석 기사 • Nov 17
Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
The board of Ipca Laboratories Limited ( NSE:IPCALAB ) has announced that it will pay a dividend of ₹2.00 per share on...분석 기사 • Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Ipca Laboratories Limited's ( NSE:IPCALAB ) price-to-earnings (or "P/E") ratio of 61.7x might make it look like a...분석 기사 • Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Ipca Laboratories Limited ( NSE:IPCALAB ) recently...분석 기사 • May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Ipca...분석 기사 • Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
With a price-to-earnings (or "P/E") ratio of 61.8x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...분석 기사 • Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...주주 수익률
| IPCALAB | IN Pharmaceuticals | IN 시장 | |
|---|---|---|---|
| 7D | 9.9% | 3.3% | 1.0% |
| 1Y | 25.0% | 12.6% | -1.3% |
수익률 대 산업: IPCALAB은 지난 1년 동안 12.6%의 수익을 기록한 Indian Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: IPCALAB은 지난 1년 동안 -1.3%를 기록한 Indian 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
안정적인 주가: IPCALAB는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: IPCALAB의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1949 | 16,778 | Pranay Godha | www.ipca.com |
제약 회사인 Ipca Laboratories Limited는 인도, 유럽, 아프리카, 미주, 아시아, CIS 및 오스트랄라시아에서 다양한 치료 부문을 위한 제형 및 활성 제약 성분(API)을 제조 및 판매하는 회사입니다. 항고혈압제, 항말라리아제, 이뇨제, DMARD 및 구충제 등의 치료 분야에서 API를 제공합니다. 또한 알레르기, 항종양/항암제, 항관절염제, 항간질제, 항고혈압제, 심장학, 당뇨병, 피부과, 당뇨병학, 완화제/보호제, 발열, 위장병학 등 치료 분야에서 제네릭 및 브랜드 제형을 제공하고 있으며, 혈액학, 피부과, 당뇨병학, 항생제, 항말라리아제, 항생제, 항생제, 항암제 등 치료 분야에 대한 의약품을 공급하고 있습니다, 혈액학, 기생충, 간 보호제, 면역 억제제, 감염성 질환, 말라리아, 신경학, 신경병증성 통증, NSAID, 건강기능식품, 안과, 경구용 항당뇨제, 정형외과, 프로바이오틱스, 정신과, 호흡기, 류마티스, 비뇨기과 등 다양한 분야의 의약품을 생산하고 있습니다.
Ipca Laboratories Limited 기초 지표 요약
| IPCALAB 기초 통계 | |
|---|---|
| 시가총액 | ₹451.31b |
| 순이익 (TTM) | ₹11.41b |
| 매출 (TTM) | ₹96.46b |
39.6x
주가수익비율(P/E)4.7x
주가매출비율(P/S)IPCALAB는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| IPCALAB 손익계산서 (TTM) | |
|---|---|
| 매출 | ₹96.46b |
| 매출원가 | ₹28.23b |
| 총이익 | ₹68.24b |
| 기타 비용 | ₹56.82b |
| 순이익 | ₹11.41b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 44.98 |
| 총이익률 | 70.74% |
| 순이익률 | 11.83% |
| 부채/자본 비율 | 7.4% |
IPCALAB의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
0.3%
현재 배당 수익률13%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/03 11:50 |
| 종가 | 2026/07/03 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Ipca Laboratories Limited는 37명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |